The Economics of Biosimilars: Improving Market Access, Sustainable Pricing and Reimbursement Policies

June 29, 2022 2:00pm

Sonia Oskouei
Vice President, Biosimilars
Cardinal Health

Chad A. Landmon
Axinn, Veltrop & Harkrider LLP

Juliana “Julie” Reed
Executive Director
The Biosimilars Forum

Mandy C. Leonard
Senior Director, Drug Use Policy and Formulary Management
Cleveland Clinic


Ali I. Ahmed
Senior Vice President, Biosimilars
Fresenius Kabi USA

  • Evaluating the clinical pipeline by company, indication and phase
    • Analyzing the market share for biosimilars in the United States
    • Target drugs with highest spending
    • Current market dynamics and considerations for biosimilar adoption
    • Comparing the European Union biosimilar experience
  • Considering the implications of insurers placing biosimilars on “primary tiers” and what that means for the future
  • Reviewing the implications of the House passed Lower Drug Costs Now Act
    • Understanding the implications of empowering the government to negotiate directly with manufacturers